Increased serum 72 KDa metalloproteinase in serous ovarian tumors: Comparison with CA 125

Anticancer Research

Volumn 16, Issue 4 A, 1996, Pages 2123-2127

  Garzetti, Giuseppe Gioele ^a   Ciavattini, Andrea ^a   Lucarini, Guendalina ^a   Goteri, Gaia ^a   Romanini, Carlo ^b   Biagini, Graziella ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

72 KDa metalloproteinase; Ovary; Serous cystadenocarcinoma; Serous cystadenoma; Serum

Indexed keywords

CA 125 ANTIGEN; COLLAGEN TYPE 4; GELATINASE; METALLOPROTEINASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAGEN METABOLISM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTADENOCARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; OVARY TUMOR; PRIORITY JOURNAL; TUMOR CELL;

ADULT; AGED; BASEMENT MEMBRANE; CA-125 ANTIGEN; CYSTADENOCARCINOMA, SEROUS; CYSTADENOMA, SEROUS; FEMALE; GELATINASES; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; METALLOENDOPEPTIDASES; MIDDLE AGED; OVARIAN NEOPLASMS; REFERENCE VALUES; REGRESSION ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0029760197     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Liotta LA, Stetler-Stevenson GM: Metalloproteinase and cancer invasion. Semin Cancer Biol 1: 99-106, 1990.
2. Liotta LA, Stetler-Stevenson GM: Metalloproteinase and malignant conversion: Does correlation imply causality? J Natl Cancer Inst 81: 556-571, 1989.
3. Takemura M, Azuma C, KimuraT, Kanai T, Saji F, Tanizawa O: Type-IV collagenase and tissue inhibitor of metalloproteinase in ovarian cancer tissue. Int J Gynecol Obstet 46: 303-309, 1994.
4. Monteagudo C, Merino MJ, SanJuan J, Liotta LA, Stetler-Stevenson WG: Immunohistochemical distribution of the type IV collagenase in normal, benign and malignant breast tissue. Am J Pathol 136: 585-592, 1990.
5. Senback F, Wasenius V: Basement structure in tumors of the ovary. Eur J Obstet Gynecol Reprod Biol 20: 357-371, 1985.
6. Stenback F: Benign, borderline and malignant serous cystadenomas of the ovary: A transmission and scanning electron microscopical study. Pathol Res Pract 172: 58-72, 1981.
7. Campo E, Merino MJ, Tavassoli FA: Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol 16: 500-507, 1992.
8. Helzlsouer KJ, Bush TL, Alberg AJ, Bass KM, Zacur H, Comstock GW: Prospective study of serum CA 125 levels as markers of ovarian cancer. JAMA 269: 1123-1126, 1993.
9. Welander CE: What do CA 125 and other antigens tell us about ovarian cancer biology? ACTA Obstet Gynecol Scand 71S: 85-93, 1992.
10. Wacher MP, Krutzsch HC, Liotta LA, Steler-Stevenson WG: Development of a novel substrate capture immunoassay for the detection of a neutral metalloproteinase capable of degrading basement membrane (type IV) collagen. J Immunol Methods 126: 239-245, 1990.
11. D'Errico A, Biagini G, Garbisa S, et al: Detection of extracellular matrix antigen (fibronectin, laminin, type IV collagen) in paraffin embedded sections by avidinbiotin-peroxidase complex labeling. Bas Appl Histochem 30: 325-332, 1986.
12. Daidone MG, Silvestrini R, D'Errico A et al: Laminin receptors, collagenase IV and prognosis in node negative breast cancer. Int J Cancer 47: 529-532, 1991.
13. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafle S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 84: 67, 1980.
14. Kobayashi H, Kawashima Y: Clinical usefulness of the combination assay of CA 125, SLX, and CA 72.4 in patients with ovarian cancer. ACTA Obst Gynaec Jap 41: 1731-1735, 1989.
15. Hernadi Z, Molnar V, Juhasz B, Polka R, Margitai B: Predictive value of the tumor marker combination CA 125 and beta2-microglobulinemia in ovarian cancer. Zentralbl Gynakol 114: 6-9, 1992.
16. Nishida Y, Kohno K, Kawamata T, Morimitsu K, Kuwano M, Miyakawa I: Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA 125 and CA 72-4. Gynecol Oncol 56: 357-361, 1995.
17. Hogdall CK, Mogensen O, Tabor A, Mogensen B, Jakobsen KM, NorgaardPedersen B, Larsen SO, Clemmensen I: The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors. Gynecol Oncol 56: 22-28, 1995.